Clinical Trial Update: Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the radiotracer 68Ga-NOTA-AE105 for PET-based diagnosis of aggressive cancers, including breast cancer, prostate cancer, and u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Prostate Cancer
• Urinary Bladder Cancer

Drugs mentioned

• 68Ga-NOTA-AE105 (NOTA-AE105 radiotracer)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Breast Cancer, Prostate Cancer | Phase 1 | Status: COMPLETED